Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease

Molecular Neurobiology

Volumn 49, Issue 2, 2014, Pages 784-795

  Anglada Huguet, Marta ^a,b,c   Xifró, Xavier ^a,b,c,d   Giralt, Albert ^a,b,c   Zamora Moratalla, Alfonsa ^e   Martín, Eduardo D ^e   Alberch, Jordi ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY OF GIRONA   (Spain)

^e UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

GluA1; Hippocampus; Huntingtin; Long term potentiation; PSD 95; Striatum

Indexed keywords

8 CHLORODIBENZ[B,F][1,4]OXAZEPIN 10(11H) CARBOXYLIC ACID 2 [ 1 OXO 3 ( 4 PYRIDINYL)PROPYL]HYDRAZIDE; BIOLOGICAL MARKER; HUNTINGTIN; NEUROPROTECTIVE AGENT; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E2 RECEPTOR EP1 ANTAGONIST; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; QUINOLINIC ACID; SC 51089; UNCLASSIFIED DRUG; HYDRAZINE DERIVATIVE; OXAZEPINE DERIVATIVE;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; HIPPOCAMPUS; HUNTINGTON CHOREA; LONG TERM MEMORY; LONG TERM POTENTIATION; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROMODULATION; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OSMOTIC MINIPUMP; PROTEIN EXPRESSION; ROTAROD TEST; SYNAPSE; T-MAZE TEST; TASK PERFORMANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CBA MOUSE; DISEASE MODEL; GENETICS; HUNTINGTON DISEASE; MEMORY DISORDERS; METABOLISM; MOTOR SKILLS DISORDERS; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; HYDRAZINES; MALE; MEMORY DISORDERS; MICE; MICE, INBRED CBA; MICE, TRANSGENIC; MOTOR SKILLS DISORDERS; OXAZEPINES; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE;

EID: 84896545094     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8556-x     Document Type: Article

References (58)

1. HDCRG (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72:971-983
2. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369-384 (Pubitemid 28237321)
3. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, Robbins TW, Sahakian BJ (1998) Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 121(Pt 7):1329-1341 (Pubitemid 28327409)
4. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R (2004) Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation - a longitudinal follow-up study. J Neurol 251:935-942 (Pubitemid 39119311)
5. Giralt A, Puigdellivol M, Carreton O, Paoletti P, Valero J, Parra-Damas A, Saura CA, Alberch J, Gines S (2012) Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum Mol Genet 21:1203-1216
6. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20:5115-5123 (Pubitemid 30421714)
7. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85:5733-5737
8. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577 (Pubitemid 16196286)
9. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60:1615-1620 (Pubitemid 36618087)
10. Spargo E, Everall IP, Lantos PL (1993) Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 56:487-491 (Pubitemid 23171778)
11. Reddy PH, Shirendeb UP (2012) Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim Biophys Acta 1822:101-110
12. Li JY, Plomann M, Brundin P (2003) Huntington's disease: a synaptopathy? Trends Mol Med 9:414-420 (Pubitemid 37309642)
13. Milnerwood AJ, Cummings DM, Dallerac GM, Brown JY, Vatsavayai SC, Hirst MC, Rezaie P, Murphy KP (2006) Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum Mol Genet 15:1690-1703 (Pubitemid 43904835)
14. Raymond LA, Andre VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS (2011) Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 198:252-273
15. Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83-98
16. Ahmad AS, Saleem S, Ahmad M, Dore S (2006) Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 89:265-270 (Pubitemid 43013774)
17. Hewett SJ, Bell SC, Hewett JA (2006) Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. Pharmacol Ther 112:335-357 (Pubitemid 44486408)
18. Koch H, Huh SE, Elsen FP, Carroll MS, Hodge RD, Bedogni F, Turner MS, Hevner RF, Ramirez JM (2010) Prostaglandin E2-induced synaptic plasticity in neocortical networks of organotypic slice cultures. J Neurosci 30:11678-11687
19. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG, Rowan M, Cleary J, Wallis RA, Sun GY, Cole G, Frautschy S, Anwyl R, Ashe KH (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131:651-664 (Pubitemid 351294724)
20. Yang H, Zhang J, Breyer RM, Chen C (2009) Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. J Neurochem 108:295-304
21. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41:661-690 (Pubitemid 32385902)
22. Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Dore S (2005) Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res 1066:71-77 (Pubitemid 41790730)
23. Bilak M, Wu L, Wang Q, Haughey N, Conant K, St HC, Andreasson K (2004) PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol 56:240-248 (Pubitemid 39037919)
24. McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, Andreasson K (2004) Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24:257-268 (Pubitemid 38181690)
25. Carrasco E, Casper D, Werner P (2007) PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J Neurosci Res 85:3109-3117 (Pubitemid 350057366)
26. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12:225-229 (Pubitemid 43214750)
27. Zhen G, Kim YT, Li RC, Yocum J, Kapoor N, Langer J, Dobrowolski P, Maruyama T, Narumiya S, Dore S (2012) PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease. Neurobiol Aging 33:2215-2219
28. Kitaoka S, Furuyashiki T, Nishi A, Shuto T, Koyasu S, Matsuoka T, Miyasaka M, Greengard P, Narumiya S (2007) Prostaglandin E2 acts on EP1 receptor and amplifies both dopamine D1 and D2 receptor signaling in the striatum. J Neurosci 27:12900-12907 (Pubitemid 350159587)
29. Andreasson K (2010) Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 91:104-112
30. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506 (Pubitemid 26374323)
31. Giralt A, Rodrigo T, Martin ED, Gonzalez JR, Mila M, Cena V, Dierssen M, Canals JM, Alberch J (2009) Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience 158:1234-1250
32. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martin-Ibanez R, Munoz MT, Mengod G, Ernfors P, Alberch J (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci 24:7727-7739 (Pubitemid 39186828)
33. Giralt A, Carreton O, Lao-Peregrin C, Martin ED, Alberch J (2011) Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol Neurodegener 6:71
34. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22:1592-1599 (Pubitemid 35386278)
35. Giralt A, Saavedra A, Carreton O, Xifro X, Alberch J, Perez-Navarro E (2011) Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum Mol Genet 20:4232-4247
36. Anglada-Huguet M, Giralt A, Perez-Navarro E, Alberch J, Xifro X (2012) Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease. J Neurochem 121:639-648
37. Xifro X, Giralt A, Saavedra A, Garcia-Martinez JM, Diaz-Hernandez M, Lucas JJ, Alberch J, Perez-Navarro E (2009) Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. Neurobiol Dis 36:461-469
38. Giralt A, Friedman HC, Caneda-Ferron B, Urban N, Moreno E, Rubio N, Blanco J, Peterson A, Canals JM, Alberch J (2010) BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Ther 17:1294-1308
39. Martin ED, Buno W (2005) Stabilizing effects of extracellular ATP on synaptic efficacy and plasticity in hippocampal pyramidal neurons. Eur J Neurosci 21:936-944 (Pubitemid 40461047)
40. Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol 90:230-245
41. Nithianantharajah J, Barkus C, Murphy M, Hannan AJ (2008) Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol Dis 29:490-504
42. Torres-Peraza JF, Giralt A, Garcia-Martinez JM, Pedrosa E, Canals JM, Alberch J (2008) Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. Neurobiol Dis 29:409-421
43. Bauer PO, Wong HK, Oyama F, Goswami A, Okuno M, Kino Y, Miyazaki H, Nukina N (2009) Inhibition of Rho kinases enhances the degradation of mutant huntingtin. J Biol Chem 284:13153-13164
44. Cowin RM, Roscic A, Bui N, Graham D, Paganetti P, Jankowsky JL, Weiss A, Paylor R (2012) Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. Behav Brain Res 229:308-319
45. Li X, Rose SE, Montine KS, Keene CD, Montine TJ (2012) Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid beta neurotoxicity in vitro. J Neuroimmune Pharmacol 8(1):87-93
46. Berridge MJ, Bootman MD, Lipp P (1998) Calcium - a life and death signal. Nature 395:645-648 (Pubitemid 28475949)
47. Wojda U, Salinska E, Kuznicki J (2008) Calcium ions in neuronal degeneration. IUBMB Life 60:575-590
48. Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF, Brundin P (2001) Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 14:1492-1504 (Pubitemid 35463716)
49. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181-192 (Pubitemid 29262475)
50. Zhang L, Jiang L, Sun Q, Peng T, Lou K, Liu N, Leng J (2007) Prostaglandin E2 enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. Mol Cell Biochem 305:19-26 (Pubitemid 47517163)
51. Paoletti P, Vila I, Rife M, Lizcano JM, Alberch J, Gines S (2008) Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J Neurosci 28:10090-10101
52. Tang TS, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 27:7899-7910 (Pubitemid 47173323)
53. Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, Young AB, Standaert DG, Thompson LM, Cha JH (2003) Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol Dis 14:624-636 (Pubitemid 37543539)
54. Jarabek BR, Yasuda RP, Wolfe BB (2004) Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 127:505-516 (Pubitemid 38295468)
55. Usdin MT, Shelbourne PF, Myers RM, Madison DV (1999) Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum Mol Genet 8:839-846 (Pubitemid 29189051)
56. Brooks SP, Jones L, Dunnett SB (2012) Comparative analysis of pathology and behavioural phenotypes in mouse models of Huntington's disease. Brain Res Bull 88:81-93
57. Chen X, Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I (2011) Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol Neurodegener 6:81
58. Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101:57-66